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Abstract
Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic
arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down
of T cell activation with ensuing tumor immune escape. While the impact of arginine depletion on polyclonal T cell
proliferation and cytokine secretion is well documented, its influence on chemotaxis, cytotoxicity and antigen specific
activation of human T cells has not been demonstrated so far. We show here that chemotaxis and early calcium signaling of
human T cells are unimpaired in the absence of arginine. We then analyzed CD8+ T cell activation in a tumor peptide as well
as a viral peptide antigen specific system: (i) CD8+ T cells with specificity against the MART-1aa26–35*A27L tumor antigen
expanded with in vitro generated dendritic cells, and (ii) clonal CMV pp65aa495–503 specific T cells and T cells retrovirally
transduced with a CMV pp65aa495–503 specific T cell receptor were analyzed. Our data demonstrate that human CD8
+ T cell
antigen specific cytotoxicity and perforin secretion are completely preserved in the absence of arginine, while antigen
specific proliferation as well as IFN-c and granzyme B secretion are severely compromised. These novel results highlight the
complexity of antigen specific T cell activation and demonstrate that human T cells can preserve important activation-
induced effector functions in the context of arginine deficiency.
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Introduction
The fate of a growing tumor is not only based on the
proliferative capacity of the cancer cell itself but rather dictated
by the complex interplay of various invading cell types, most
prominently antitumoral and regulatory immune cells. The
endogenous or therapy-induced antitumoral immune attack is
often inhibited by tumor immune escape mechanisms [1], [2].
Among these, so-called myeloid-derived suppressor cells (MDSC)
inhibit effectively antitumoral adaptive immune responses mainly
by the production of reactive oxygen intermediates and by the
expression of the arginine-metabolizing enzymes nitric oxide
synthase and arginase [3,4]. Two mammalian arginase isoforms
exist, which both hydrolyze arginine to ornithine and urea [5].
The isoforms differ with respect to cellular and subcellular
expression and regulation. Murine and human MDSC have been
shown to express the hepatic isoform arginase I constitutively or
inducibly [6]. Arginase I-mediated arginine depletion in the tumor
microenvironment leads to inhibition of T lymphocyte prolifera-
tion, cytokine synthesis and anti-tumor immune responses [6,7]. In
human T lymphocytes, the absence of arginine induces a
downregulation of the signal transducing T cell receptor-associ-
ated f chain [8,9], impairs dephosphorylation of the actin-binding
protein cofilin [10] and inhibits progression through the cell cycle
via induction of a G0–G1 arrest [11].
The defect of the adaptive immune system due to arginase-
mediated arginine depletion is causally responsible for the
unrestricted tumor growth in various murine tumor models [12]
and human tumor entities [12,13,14]. Arginase inhibition or
arginine substitution can reconstitute polyclonal human T cell
reactivity [12] or induce tumor cell death [14] in primary material
from human cancer patients in vitro.
The influence of arginine depletion on the antitumoral immune
response of antigen-experienced human CD8+ T lymphocytes
with defined tumor antigen specificity has not been demonstrated
so far. For an effective antitumoral adaptive immune response, T
cells have to migrate within the tumor microenvironment and –
after recognition of tumor-associated cognate peptides and TCR-
mediated activation – perform various effector functions (cytotoxic
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killing, secretion of cytokines) as well as initiate proliferation and
differentiation to expand clone size and generate effector and
memory cells. A detailed analysis of these various aspects of T cell
activation is important for the situation in tumor patients in vivo
upon antigen specific antitumoral vaccination and is especially
relevant in light of the minimal success of protein-, peptide- or
dendritic cell (DC)-based cancer vaccines [15]. Although the
expansion of tumor specific T lymphocytes with in vitro antitu-
moral activity has been demonstrated in various vaccination
protocols of patients, this does not translate into effective tumor
regression [16,17]. Clinical inefficiency correlates with the
presence of functionally inactive tumor-infiltrating lymphocytes
within the tumor stroma [14] whereas they can regain functional
potential outside the tumor microenvironment [18,19].
Among a variety of known tumor antigens, the superior T cell
immunogenicity of the tumor antigen MART-1aa26–35 (melanoma-
associated antigen recognized by T cells, amino acids 26–35) was
demonstrated in numerous in vitro analyses [20] and also clinical
trials [21]. Furthermore the MART-1aa26–35*A27L analogue
peptide, with a substitution of the amino acid alanine (A) by
leucine (L) at position 27 showed superior immunogenicity [21].
While MART-1 is expressed quite selectively on malignant
melanoma cells, there is also cross reactivity with multiple
myeloma [22], bronchial [23] and renal cancer cells [24], due to
a homologue peptide sequence between MART-1 and the
HM1.24 antigen. Therefore, MART-1aa26–35*A27L is an ideal
model antigen in order to analyze tumor specific T cell responses
covering numerous tumor entities.
We report here that human T cell chemotaxis, early calcium
signaling and MART-1aa26–35*A27L specific CD8
+ T cell mediated
cytotoxicity are uncompromised in the absence of arginine while
interferon-gamma (IFN-c) and granzyme B secretion are sup-
pressed when tumor antigen specific T cells were restimulated with
the cognate peptide under arginine-limiting conditions. We
validate these results in an alternative CMV pp65aa495–503 peptide
specific system with expanded CMV pp65aa495–503 specific T cells
as well as T cells retrovirally transduced with a pp65aa495–503
specific T cell receptor (TCR).
Materials and Methods
Blood Samples and Ethics Statement
To analyze the activation of T cells, peripheral blood/buffy
coats from healthy donors (HD) were used. All human studies were
performed after obtaining written informed consent in accordance
with the Declaration of Helsinki and were approved by the
Landesaerztekammer Rhineland-Palatine Ethics Committee and
the ethics committee of the Medical Faculty, University of
Heidelberg according to the institutional guidelines. Data safety
management was performed according to the data safety
regulations of the University Hospitals Heidelberg and Mainz.
Cell Culture Medium and Reagents
If not specified otherwise, cells were maintained in RPMI 1640
cell culture medium with penicillin/streptomycin and 2 mM L-
glutamine (all from PAA Laboratories, Pasching, Austria), either
with 10% heat inactivated fetal calf serum (FCS) for cell lines or
5% heat inactivated human serum (both from PAA Laboratories)
for primary cells. Arginine-free RPMI 1640 cell culture medium
was purchased from PromoCell (Heidelberg, Germany) and
supplemented with penicillin/streptomycin, 2 mM L-glutamine,
10% heat inactivated dialyzed FCS (PAA Laboratories) and
10 mM MnCl2. Arginine-free cell culture medium was supple-
mented with L-arginine to obtain medium with arginine. Unless
otherwise specified, reagents were purchased from Sigma (Sigma-
Aldrich, Steinheim, Germany).
Peptides
The MART-1aa26–35*A27L peptide (ELAGIGILTV) and HLA-
A2 restricted irrelevant control peptide (LLIIVILGV; as a control
for unspecific, non-tumor antigen mediated T cell activation) were
synthesized by the peptide synthesis facility of the German Cancer
Research Center Heidelberg using standard procedures. CMV
pp65aa495–503 peptide (NLVPMVATV) was purchased from
Biosyntan, Berlin, Germany.
Isolation of PBMC and T cells
Peripheral blood mononuclear cells (PBMC) were purified from
peripheral blood/buffy coats by ficoll-hypaque density gradient
purification (Biochrom, Berlin, Germany). Purified T cells were
obtained from PBMC using a T cell Isolation Kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s
protocol.
Expansion of MART-1aa26–35*A27L Specific T cells
PBMC from HLA-A*02+ HD (Institute of Immunology and
IKTZ, University of Heidelberg, Heidelberg, Germany) were used
to generate antigen specific T cells. Immature DC were obtained
by culturing plastic adherent PBMC for 5 days with GM-CSF
(800 U/ml, Sargramostim, Bayer, Seattle, WA, USA) and IL-4
(500 U/ml, R&D Systems, Minneapolis, MN, USA). Maturation
of immature DC was then induced by culturing the cells for 2 days
in the presence of TNF-a (10 ng/ml, R&D Systems), IL-6
(1000 U/ml, PromoCell) and prostaglandin E2 (1 mg/ml, Bio-
mol/Enzo Lifesciences, Lo¨rrach, Germany). Simultaneously,
MART-1aa26–35*A27L peptide (10 mg/ml) was added to load DC.
Afterwards, autologous PBMC were incubated for 7 days together
with mature DC in the presence of 5% human serum and IL-2
(50 IE/ml, Proleukin, Chiron GmbH, Munich, Germany) to
expand MART-1aa26–35*A27L specific T cells. In case of cytotox-
icity assays, incubation was extended to 28 days and restimulations
with MART-1aa26–35*A27L peptide pulsed T2 cells were performed
(along with culture medium and IL-2 renewal) on day 7, 14, and
21. T2 cells were pulsed by 2 h-incubation in serum-free medium
with a peptide concentration of 10 mg/ml.
Expansion of Human CMV pp65aa495–503 Specific T cells
PBMC were purified from buffy coats of HLA-A*0201+ as well as
HCMV seropositive donors by ficoll-hypaque separation. The isolated
cells underwent positive magnetic cell sorting (Miltenyi Biotec) to
obtain a pure CD8+ T cell subset. The untouched CD82 fraction was
loaded with 1 mg/ml pp65aa495–503 peptide for 8 h at 37uC.
Afterwards, the cells were irradiated with 3500 rad. The CD8+ T
cells were then stimulated with the irradiated, pp65aa495–503-loaded
cells in 10% human serum for initially 2 days. Starting on day 3,
human IL-2 (20 IE/ml, Roche Diagnostics GmbH, Mannheim,
Germany) and human IL-7 (5 ng/ml, R&D Systems) were additionally
supplemented. After one or two pp65aa495–503 peptide specific
restimulations as well as CMV pp65aa495–503 specific tetramer sorting
by flow cytometry a purity of .95% was reached for pp65aa495–503
peptide specific CD8+ T cells. The pp65aa495–503 specific T cell clone
T21 was kindly provided by Helga Bernhard (V. Medical Department,
Medical Center Darmstadt, Germany) and propagation of the clone
was done essentially as described [25].
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Transfection of Human T cells with CMV pp65aa495–503
Specific TCR
Retroviral transduction of the pp65aa495–503 specific TCR was
performed as described elsewhere [26] with the use of Fugene
(Roche Diagnostics) as transfection agent. The pp65aa495–503
specific TCRa (Va 18.1) and TCRb (Vb 13.1) chains [27] were
kindly provided by Mirjam Heemskerk (University Medical Center,
Leiden, The Netherlands), cloned into a modified retroviral pBullet
vector harbouring drug-selection cassettes so as to accomplish
normalized TCR expression [28]. The site-directed mutagenesis
was performed close to the CDR3a region and inside of the CDR3b
region as described [29], leading to a novel pp65aa495–503 specific
TCR. For transduction, the wild type pp65aa 495–503 specific TCR
from M. Heemskerk, the novel TCR as well as the hybrid TCRs
composed of the combined TCR chains of wild type and novel
TCR chains were used. The T cells were expanded by weekly
stimulation with anti–human CD3/CD28 beads (Invitrogen,
Darmstadt, Germany) and human IL-2 (20 IU/ml, Roche Diag-
nostics).
Chemotaxis Assay
T cells were incubated in medium (+/2 arginine) for 24 h or
48 h. Subsequently, 200 ml of the corresponding medium was
added to the lower compartment of a 96-well transwell plate (pore
size 3 mm; Corning, Lowell, MA, USA) with or without 100 ng/
ml SDF-1a (stromal cell-derived factor-1 alpha; R&D Systems,
Wiesbaden-Nordenstadt, Germany). 56104 T cells in 75 ml of
medium were transferred to the upper compartment of the
transwell plate in triplicates. To determine maximum migration
cells were pipetted to the lower compartment of the transwell
plate. After incubating the cells for 4 h, 150 ml of the cell
suspension was retained from each lower well compartment and
mixed with a calibrated plastic bead solution for quantification of
cells by flow cytometry. The percentage of migrated cells was
calculated in relation to the detected cells in the maximum
migration setting, which was set to 100%.
Calcium Flux Determined by Flow Cytometry
To determine calcium flux of T cells after activation, 16107 T
cells were incubated in the presence or absence of arginine over
night. Cells were loaded in 1 ml of fresh medium (+/2 arginine,
respectively) with the calcium indicating dye Indo 1-AM (final
concentration 2 mg/ml; Sigma-Aldrich) for 60 min at 37uC in the
dark. Next, anti-CD3 antibody (OKT3, final concentration
20 ng/ml; kindly provided by Prof. Dr. Yvonne Samstag, Institute
of Immunology, University of Heidelberg, Heidelberg, Germany)
or isotype control IgG2a (BD Biosciences, Heidelberg, Germany)
were added to the cells and incubated for additional 10 min at
room temperature. Flow cytometric analysis (LSRII flow cytom-
eter, BD Biosciences) was done as follows: after measurement of
unstimulated cells for 3 min, cross-linking goat-anti-mouse-
IgG+IgM antibody (final concentration 10 mg/ml, Dianova,
Hamburg, Germany) was added and cells were analyzed for
additional 3 min. As a positive control, cells were then activated by
ionomycin (final concentration 1 mM; Merck, Darmstadt, Ger-
many).
IFN-c ELISPOT and IFN-c/Granzyme B/Perforin ELISA
CD8+ cells were purified from the MART-1aa26–35*A27L activated
and expanded T cell population using positive immunomagnetic
cell sorting (MACS-system, Miltenyi Biotec). Purified CD8+ cells
were then incubated with MART-1aa26–35*A27L peptide or irrele-
vant peptide pulsed T2 cells (2 h incubation with 10 mg/ml peptide)
as targets for 24 h in anti-IFN-c antibody (Mabtech, Nacka Strand,
Sweden) coated nitrocellulose-plates (Millipore, Schwalbach, Ger-
many) and plate-bound IFN-c was subsequently detected as
described previously [22]. To analyze MART-1aa26–35*A27L specific
IFN-c synthesis by CD8+ cells, a E:T ratio of 1:5 was used.
The concentration of IFN-c in the supernatant of T cell
activation cultures was determined as previously published [9].
Briefly, supernatants of stimulation cultures were harvested and
cytokine concentrations were measured by specific capture ELISA
according to the manufacturer’s instructions (BD Biosciences). All
stimulation conditions were performed at least in triplicates.
Granzyme B and perforin concentrations in ELISPOT or cell
culture supernatants were also determined by ELISA according to
manufacturer’s instructions (Mabtech). ELISA microplates were
purchased from Greiner Bio-One (Frickenhausen, Germany).
Intracellular IFN-c Analysis by Flow Cytometry
The expression of intracellular IFN-c and different surface T
cell markers was measured by flow cytometry. After activation of
MART-1aa26–35*A27L expanded PBMC with MART-1aa26–35*A27L
or irrelevant peptide loaded T2 cells for 20 h, 10 mg/ml brefeldin
A (Biomol/Enzo Lifesciences) were added to the cell culture 4 h
prior to staining. Then cells were fixed in 4% paraformaldehyde
(J.T. Baker, Deventer, Holland) for 10 min at room temperature.
After washing, the cells were permeabilized with saponin buffer
(PBS with 0.5% BSA, 5% FCS, 0.1% saponin and 0.1% NaN3) for
10 min at room temperature. Cells were then incubated with
fluorochrome-labeled antibodies against CD3, CD8, CD28 and
IFN-c (all from BD Biosciences) according to the manufacturer’s
instructions. As controls cells were stained with the corresponding
isotype antibodies. After a final washing with saponin buffer, cells
were resuspended in 0.5% paraformaldehyde in PBS. Flow
cytometry analysis was performed with a FACS Calibur flow
cytometer (BD Biosciences).
Cytotoxicity Assay ([51Cr]-Chromium Release Assay)
In case of the MART-1 antigen model, CD8+ cells were purified
from the MART-1aa26–35*A27L activated and expanded T cell
population using negative immunomagnetic cell sorting (CD8+ T
cell isolation Kit, Miltenyi Biotec) and preincubated in the
respective medium (+/2 arginine) for 24 h. The next day T2
cells were pulsed with MART-1aa26–35*A27L or irrelevant peptide
(10 mg/ml, 2 h-incubation in serum-free medium) and subse-
quently labeled with [51Cr]-Chromium (final concentration:
125 mCi/ml; Hartmann Analytic, Braunschweig, Germany) for
another 2 h in medium with 5% human serum. Finally, 104
labeled T2 cells were seeded out in 96-well round-bottom plates
with effector cells in different ratios (E:T range 1:1–20:1). After an
incubation period of 4 h (37uC, 5% CO2), 75 ml of each
supernatant were harvested and analyzed using a c-counter
(Perkin Elmer, Boston, MA, USA). Spontaneous and maximal
release of [51Cr]-Chromium were determined by analyzing
supernatants of T2 cell cultures without effector cells either in
presence of medium (spontaneous release) or 2% Igepal CA-630
(maximal release). Specific lysis was calculated as follows: [(test –
spontaneous release)/(maximal release – spontaneous re-
lease)6100 = % specific lysis]. All experiments were performed
in duplicates.
In the CMV specific model, K562-A2 cells were used as target
cells, loaded with pp65aa495–503 peptide at 3 different concentra-
tions (1 nM, 10 nM, 100 nM) and labeled with [51Cr]-Chromium
for 1.5 h. After washing, target cells were seeded in a 96-well
round bottom plate and effector cells were added. After an
incubation period of 4 h, 80 ml supernatant were harvested. The
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spontaneous and maximal release was determined in the presence
of either medium or 1% Triton X-100, respectively.
Tetramer Analysis
MART-1aa26–35*A27L specific T cells were quantified in the
expanded T cell population by staining with PE-labeled tetrameric
MHC complexes loaded with the peptide ELAGIGILTV (iTAG
MHC Tetramer; Beckman Coulter, Fullerton, CA, USA) accord-
ing to the manufacturer’s protocol. Additionally cells were stained
with fluorochrome-labeled antibodies against CD3 and CD8 (BD
Biosciences) according to the manufacturer’s instructions. Finally
cells were resuspended in 0.5% paraformaldehyde in PBS and
analyzed using a FACS Calibur flow cytometer (BD Biosciences).
Proliferation Analysis
For proliferation analysis via [3H]-Thymidine incorporation,
the cells were pulsed with 1 mCi/well [3H]-Thymidine (GE
Healthcare, Buckinghamshire, U.K.) after 48 h and incubated
for another 16 h. Cells were harvested on glass fiber filters using
an automatic cell harvester and the incorporation of [3H]-
Thymidine was measured in a microplate scintillation counter.
The K562-A2 cells were irradiated with 3500 rad before the assay.
For CFSE-based analysis, T cells were labeled with 0.5 mM CFSE
(Invitrogen, Karlsruhe, Germany) for 15 minutes at 37uC,
centrifuged, incubated another 30 min in prewarmed cell culture
medium and subsequently used for cell activation assays. Cells
were then analyzed by flow cytometry.
Figure 1. Arginine-independent T cell functions: chemotaxis and calcium flux. A Purified primary human T cells were preincubated either
for 24 h or 48 h in the presence (+Arg, 1000 mM) or absence (2Arg, 0 mM) of arginine. They were then placed in the respective media into the upper
compartment of a trans-well plate, whereas a chemokine (SDF-1a) was added to the lower compartment of the well. Wells without chemokine were
also set up to detect spontaneous migration of cells. Maximum migration was determined by adding the same number of T cells to the lower
compartment of a separate well. After 4 h cells in the lower compartment were quantified flow-cytometrically. Migration of T cells (%) was calculated
relatively to the maximummigration which was set to 100%. Shown are summarized mean values and standard deviations of results from 3 individual
experiments. NS: not significant. B Calcium signaling in primary human T cells in the presence (+ Arg, 1000 mM) or absence (2Arg) of arginine was
analyzed by flow cytometry using the calcium indicating dye Indo 1-AM. The ratio of Indo-1 violet/Indo-1 blue correlates directly with the amount of
calcium in the cell. T cells were preincubated with OKT-3 antibody and calcium levels of resting cells were monitored for 3 min. The cells were then
stimulated by adding a crosslinking antibody ( = stimulus), which led to increasing calcium levels irrespective of arginine. As a negative control,
isotype control antibody was used instead of OKT-3. Finally, the calcium ionophore ionomycin was added as a positive control. One representative
analysis (total number of experiments = 3) is shown as a histogram plot overlay.
doi:10.1371/journal.pone.0063521.g001
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Statistical Analysis
Differences between T cell activation with or without arginine
were analyzed by student’s t-test using the Statistica for Windows
software (StatSoft, Tulsa OK, USA). Chemotaxis assays were
analyzed by One-way ANOVA with Tukey’s multiple compari-
sons test. Differences in the number of spots per well in the IFN-c
ELISPOT experiments between T2 cells loaded with MART-
1aa26–35*A27L compared to T2 cells loaded with an irrelevant
peptide were also calculated by student’s t-test and ELISPOTs
were defined as positive, if MART-1aa26–35*A27L peptide activation
achieved at least 10 spots more than control peptide and if the
difference was significant (p,0.05).
Results
Arginine Deficiency does not Inhibit Chemotactic
Movement and Early Calcium Signaling of Human T cells
In order to analyze chemokine-induced migration of human T
cells in the context of arginine deficiency we analyzed the amount
of migrated T cells upon incubation with and without the
chemokine SDF-1a in a transwell system in the absence or
presence of arginine. Notably, the cells had been preincubated for
either 24 h or 48 h already in the respective media in order to
subject them to arginine deficiency for extended periods of time
before the chemokine assay was started. As demonstrated in
Fig. 1A, T cells were able to migrate along the SDF-1a chemokine
gradient irrespective of arginine. Summarizing 3 individual
experiments, 7.7% 61.9% (24 h) or 8.9% 60.9% (48 h) of the
T cells migrated in the presence of arginine and 6.7% 61.2%
(24 h) or 7.9%61.1% (48 h) in the absence of arginine. There was
no significant difference regarding T-cell migration between
arginine-bearing or arginine-deficient conditions after 24 h
(p = 0.71) or 48 h (p = 0.79). Spontaneous T cell migration was
also not different: 0.07% 60.03% (24 h) and 0.14% 60.08%
(48 h) with arginine vs. 0.07%60.03% (24 h) and 0.14%60.07%
(48 h) without arginine (p.0.99 for both time points). Note that
SDF-1a induced an up to 100 fold increase in the amount of
migrated cells compared to spontaneous migration (p,0.0001 for
each condition).
Next, we assessed activation-induced early calcium signaling in
human T cells. We stimulated primary human T cells via their
TCR and measured intracellular calcium flux flow-cytometrically
(Fig. 1B). Again, T cells had been preincubated in the respective
media overnight to mimic in vivo adaptation towards an arginine-
deprived micromilieu. In 3 individual experiments we reproduc-
ibly saw that arginine deficiency did not impair TCR-triggered
calcium flux in human T cells.
Arginine Depletion Leads to Inhibition of IFN-c and
Granzyme B Secretion by Tumor Antigen Specific Human
CD8+ T cells, Whereas Perforin Secretion is Unimpaired
Effective CD8+ T cell-mediated tumor control most likely
depends on an unimpaired synergistic cooperation of various
different T cell effector functions. Apart from activation-induced
secretion of important effector cytokines like IFN-c, T cells kill
tumor cells via granzyme and perforin-mediated tumor-antigen
specific cytotoxicity. We therefore analyzed the impact of arginine
deficiency on secretion of IFN-c/granzyme B/perforin and the
cytotoxic capacity of T cells in the MART-1 tumor antigen specific
model. MART-1aa26–35*A27L antigen specific T cells from HLA-
A*02+ HD were expanded by in vitro coincubation with MART-
1aa26–35*A27L pulsed donor-derived DC. Subsequently, the expand-
ed CD8+ T cells were purified after 7 days and restimulated with T2
antigen presenting cells loaded with the MART-1aa26–35*A27L
peptide or an irrelevant control peptide in the presence/absence
of arginine. IFN-c secretion was then measured as marker of T cell
activation, as it is clearly an important antitumoral effector function
of CD8+ T lymphocytes and a commonly used read-out system for
effective anti-tumor immunity [22]. This whole experimental
approach was chosen to study if memory T cell activation in the
context of antigen presenting cells and a defined prototypical tumor
antigen recapitulates the activation impairment defined in the
setting of antibody-mediated polyclonal or allogeneic stimulation
[8].
Of note, in 8 of 8 positive ELISPOT assays from individual
donors IFN-c secretion of T cells was significantly reduced
(individual p-values for all HD ,0.05) in the absence of arginine
compared to the stimulation in the presence of arginine (Fig. 2A).
When T cell activation with MART-1aa26–35*A27L peptide loaded
T2 cells in the presence of arginine is set as 100% and all 8
stimulation experiments are calculated together, median reduction
of IFN-c secretion is 63% 613% (p,0.001). In 6 of 8 activation
assays, the cytokine secretion was completely reduced to
background level in the absence of arginine (as demonstrated by
the absence of an asterisk in Fig. 2A). A representative ELISPOT
assay is demonstrated in Fig. 2B.
To confirm these data, we quantified global IFN-c secretion by
ELISA in the supernatant of T cell activation cultures in the
presence or absence of arginine. We detected measurable IFN-c
secretion in 3/3 ELISA assays. As demonstrated in Fig. 2C, we
found significantly reduced IFN-c secretion in our restimulation of
MART-1aa26–35*A27L antigen specific T cells in the absence of
arginine. Summarizing the 3 experiments, there is a median
reduction of 63% 629% (p,0.05) in T cell IFN-c secretion upon
arginine depletion as compared to the stimulation in the presence
of arginine.
In addition, we analyzed MART-1aa26–35*A27L specific T
lymphocyte IFN-c synthesis by intracellular flow cytometry. DC-
expanded human MART-1aa26–35*A27L specific T cells were
restimulated with MART-1aa26–35*A27L pulsed T2 cells in the
presence or absence of arginine in 5 HD (Fig. 3). In all HD, the
absence of arginine led to decreased amounts of IFN-c producing
CD8+ MART-1aa26–35*A27L antigen specific T cells with a median
reduction of 55% 618%, p,0.001 (Fig. 3A and 3B). Of special
interest, IFN-c producing, MART-1aa26–35*A27L specific CD8
+ T
cells expressed the CD28+ CD45RA2/low CCR7+ phenotype of
central memory T cells (Fig. 3C), representing antigen-experienced
T cells after expansion and activation by MART-1aa26–35*A27L
pulsed DC and MART-1aa26–35*A27L pulsed T2 cells.
To assess the correlation between arginine concentration and T
cell suppression, the arginine level in the medium of expanded
MART-1aa26–35*A27L antigen specific CD8
+ T cells activated by
peptide loaded T2 cells was modified. T cell responses were
subsequently analyzed by IFN-c ELISPOT assay and granzyme
B/perforin ELISA (due to technical problems granzyme B/
perforin was not measurable for HD 17, data not shown). In all 3
HD, a significant arginine concentration dependent immunosup-
pression was found below the physiological arginine concentration
of 150 mM (Fig. 4). Compared to stimulation of CD8+ T cells with
MART-1aa26–35*A27L pulsed T2 cells in 1000 mM arginine, we
found a median reduction of IFN-c spots of 3% 64% (150 mM,
p = 0.302), 23% 610% (20 mM, p = 0.017), 56% 63% (5 mM,
p,0.001) and 70% 68% (0 mM, p,0.001), respectively. The
reduction of granzyme B release was 0% 611% (150 mM,
p = 0.743), 42% 62% (20 mM, p = 0.002), 75% 66% (5 mM,
p = 0.003) and 79% 67% (0 mM, p = 0.004). Surprisingly, we
found in 2 out of 2 HD an unimpaired perforin secretion in
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stimulated MART-1aa26–35*A27L specific CD8
+ T cells in the
absence of arginine. The reduction compared to 1000 mM
arginine was 0% 64% (150 mM, p = 0.423), 1% 615% (20 mM,
p = 0.962), 16% 67% (5 mM, p = 0.085) and 10% 615% (0 mM,
p = 0.423), respectively.
Human Antigen Specific CD8+ T cell Cytotoxicity is
Completely Independent of Arginine
After demonstrating in the MART-1 antigen specific system
that arginine deprivation leads to a suppression of T cell IFN-c
synthesis comparable to the published reports on polyclonally
activated T cells, we analyzed the cytotoxic capacity of MART-
1aa26–35*A27L specific CD8
+ T cells. For this cause antigen specific
T cells were expanded with peptide loaded DC for 28 days
including weekly restimulations with peptide loaded T2 cells. To
mimic the in vivo situation more closely and to provide time for
potential metabolic adaptation we preincubated the CD8+ cells in
the respective medium (+/2 arginine) for 24 h. Figure 5 displays
the results of 3 specific [51Cr]-Chromium release assays with
MART-1aa26–35*A27L specific CD8
+ T cells from HD, in various
E:T ratios ranging from 1:1 to 20:1. Shown is the antigen specific lysis
obtained in the presence or absence of arginine. Antigen specific lysis
was calculated by subtracting specific lysis of T2 cells loaded with
control peptide from specific lysis of MART-1aa26–35*A27L loaded ones
Figure 2. Impact of arginine depletion on activation of tumor antigen specific T cells analyzed by IFN-c ELISPOT and IFN-c ELISA.
CD8+ MART-1aa26–35*A27L specific T cells were expanded by activation with MART-1aa26–35*A27L peptide loaded DC. CD8
+ T cells were then restimulated
with T2 cells loaded with MART-1aa26–35*A27L peptide or control peptide for 24 h in ELISPOT assays in the presence of arginine (+Arg, 1000 mM) or in
arginine-free cell culture medium (2Arg). A Results of all positive IFN-c ELISPOT assays are presented: Black bars depict median numbers of IFN-c
spots for T cells incubated with MART-1aa26–35*A27L peptide loaded T2 cells and white bars show stimulation with irrelevant control peptide. The
asterisks (*) indicate a positive MART-1aa26–35*A27L specific IFN-c ELISPOT. Arginine depletion led in all HD to a significant reduction of IFN-c spots (all
individual p-values ,0.05). All determinations were done at least in triplicate and each experiment was set up from a different HD (n= 8). B An
exemplary IFN-c ELISPOT assay (from HD 2) is demonstrated. C To quantify IFN-c secretion, expanded MART-1aa26–35*A27L specific CD8
+ T cells were
coincubated with MART-1aa26–35*A27L peptide loaded T2 cells for 48 h either in the absence (2Arg) or presence of arginine (+Arg, 1000 mM). IFN-c
concentrations of the supernatants were determined by IFN-c ELISA and are shown as mean of triplicates.
doi:10.1371/journal.pone.0063521.g002
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Figure 3. Impact of arginine depletion on activation of tumor antigen specific T cells analyzed by intracellular IFN-c staining. CD8+
MART-1aa26–35*A27L specific T cells of 5 HD were expanded and then restimulated by coincubation with MART-1aa26–35*A27L (black bars) or irrelevant
control peptide (white bars) loaded T2 cells either in the presence (+Arg, 1000 mM) or absence (2Arg) of arginine. After 24 h, cells were fixed,
permeabilized and stained for intracellular IFN-c as well as extracellular CD3, CD8, CD28, CD45RA and CCR7. After fixation cells were analyzed by flow
cytometry. A The fractions of IFN-c+ T cells are demonstrated relatively to the corresponding activation with MART-1aa26–35*A27L peptide pulsed T2 cells
in the presence of arginine, which was set as 100%. In all HD except of HD 12 the percentage of IFN-c+ T cells was significantly reduced in the absence of
arginine (p,0.05). B An exemplary intracellular IFN-c flow cytometry analysis (from HD 10) is demonstrated. The numbers in the quadrants show the
frequency of IFN-c+ cells as a fraction of gated CD8+CD3+ lymphocytes. C IFN-c+ CD8+CD3+ T cells express the CD28+ CD45RA2/low CCR7+ phenotype of
antigen experienced T cells. An exemplary flow cytometry analysis (from HD10) after activation with MART-1aa26–35*A27L peptide loaded T2 cells is shown.
doi:10.1371/journal.pone.0063521.g003
Figure 4. Tumor antigen specific secretion of IFN-c and granzyme B by human CD8+ T cells is regulated by the extracellular arginine
concentration, whereas perforin secretion is independent of arginine. Expanded MART-1aa26–35*A27L specific CD8
+ T cells of 3 HD were
activated with MART-1aa26–35*A27L peptide (black bars) or control peptide (white bars) loaded T2 cells in medium with different concentrations of
arginine (0, 5, 20, 150 and 1000 mM) in ELISPOT assays. After 24 h supernatants were harvested to determine granzyme B/perforin release by ELISA
and IFN-c was detected on ELISPOT membranes. A Results of ELISPOT assays are shown as mean of triplicates. The corresponding ELISPOT
membranes of activation with MART-1aa26–35*A27L peptide loaded T2 cells are shown below the diagrams. B Granzyme B/perforin concentration in
supernatants of ELISPOT assays of 2 HD determined by ELISA.
doi:10.1371/journal.pone.0063521.g004
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(Fig. 5A). Quantitative determination of antigen specific T cells was
performed by MART-1aa26–35*A27L tetramer analysis and is displayed
together with the results of the [51Cr]-Chromium release assay for each
individual experiment (Fig. 5B). In contrast to the suppression of T cell
IFN-c/granzyme B secretion, but consistent with unimpaired perforin
secretion (Fig. 4B) we found largely unimpaired T cell cytotoxicity in
the absence of arginine. The median reduction in specific lysis
compared to stimulation with arginine was 9% 67% (high E:T ratio
15:1/20:1, p = 0.153) and 13% 615% (low E:T ratio 5:1/1:1,
p = 0.206).
Impact of Arginine Depletion on Proliferation, Cytokine
Secretion and Cytotoxic Effector Function of CMV
Antigen Specific CD8+ T cells
To reassess the surprising dichotomous regulation of suppressed
(IFN-c/granzyme B secretion) versus preserved (cytotoxicity)
effector functions in a different experimental setting, we used
our well-established model of CMV peptide pp65aa495–503 specific
T cell mediated cytotoxicity. In this system, the frequency of
expanded peptide specific T cells is much higher (on average
.95% tetramer-positive T cells within the CD8+ population) than
in the MART-1aa26–35*A27L system. In a first set of experiments,
we expanded T cells from the peripheral blood of HD by in vitro
restimulation. We used these expanded CD8+ CMV reactive T
cell lines as well as a long-term CMV pp65aa495–503 specific T cell
clone (clone p21) for in vitro cytotoxicity assays at different E:T
ratios (with K562-A2 tumor cells as targets) and different
pp65aa495–503 peptide concentrations either in the presence or
absence of arginine. Again T cells were preincubated for 18 h in
the respective cell culture media before they were used for the
experimental assays. Confirming the data from the MART-
1aa26–35*A27L antigen-specific system, depletion of arginine did not
significantly inhibit CD8+ T cell-mediated cytotoxicity at all tested
E:T ratios and peptide concentrations (p.0.05 for all comparisons
between arginine-containing (+Arg; 1000 mM arginine) and
arginine-deficient media (2Arg); Fig. 6A), whereas secretion of
IFN-c (peptide concentration 100 nM: 332 pg/ml 6225 pg/ml in
+Arg medium versus 152 pg/ml 692 pg/ml in –Arg medium,
p = 0.001; peptide concentration 10 nM: 112 pg/ml 677 pg/ml
in +Arg medium versus 65 pg/ml 646 pg/ml in –Arg medium,
p = 0.017; Fig. 6B) and granzyme B (peptide concentration
100 nM: 307 pg/ml 675 pg/ml in +Arg medium versus
153 pg/ml 654 pg/ml in –Arg medium, p = 0.01; peptide
concentration 10 nM: 269 pg/ml 691 pg/ml in +Arg medium
versus 127 pg/ml 627 pg/ml in –Arg medium, p = 0.0114;
Fig. 6C) was significantly reduced in arginine free medium at
both 100 nM and 10 nM CMV pp65aa495–503 peptide concentra-
tions (above values are mean 6 SD of 3 different experiments with
a total of 5 independent HD). In contrast to the suppressed IFN-c
and granzyme B synthesis we again found unimpaired perforin
secretion in the absence of arginine also in the CMV pp65aa495–503
peptide system (Fig. 6D), recapitulating the findings in the MART-
1 experiments (see Fig. 4B). In summary, we measured 35 pg/ml
623 pg/ml in +Arg medium versus 34 pg/ml610 pg/ml in –Arg
medium, p = 0.865 for 100 nM peptide concentration and 54 pg/
ml 613 pg/ml in +Arg medium versus 47 pg/ml 68 pg/ml in –
Arg medium, p = 0.4075 for 10 nM peptide concentration;
Fig. 6D). Finally, antigen specific proliferation of CMV reactive
CD8+ T cells was again found to be strongly impaired by arginine
depletion (47% 69% of T cells in proliferation gate in +Arg
medium versus 23% 619% of T cells in proliferation gate in –Arg
medium, p = 0.029; mean 6 SD of 3 independent experiments;
representative experiment in Fig. 6E).
Effects of Arginine Depletion on Retrovirally Transduced
T cells
Finally, we addressed the question, if T cells that were
retrovirally transduced with a defined TCR might be able to
evade the suppression of antigen specific proliferation and cytokine
secretion in the context of unimpaired cytotoxicity under arginine
deficiency. This experimental approach mirrors the situation of
genetically engineered T cells for adoptive cellular immunother-
apy. We therefore transduced T cells retrovirally with a CMV
pp65aa495–503 specific TCR and used these cells for in vitro analysis
of antigen specific cytotoxicity, proliferation and cytokine secre-
tion. Summarizing two different experiments with a total of four
different TCR constructs and three independent HD, the
following results were seen: again, CD8+ T cell cytotoxicity was
completely unaffected in the absence of arginine (no significant
differences of specific lysis at all tested E:T ratios between Arg+
(1000 mM) and Arg2 (0 mM) condition; Fig. 7A), while T cell
proliferation (2133 cpm 61312 cpm in +Arg medium versus
166 cpm 6145 cpm in –Arg medium, p = 0.0008; Fig. 7B) as well
as the secretion of IFN-c (214 pg/ml 6177 pg/ml in +Arg
medium versus 88 pg/ml 6106 pg/ml in –Arg medium,
p = 0.008; Fig. 7C) and granzyme B (1535 pg/ml 61169 pg/ml
in +Arg medium versus 349 pg/ml 6162 pg/ml in –Arg medium,
p = 0.017; Fig. 7D) were strongly and significantly decreased by
arginine depletion. Again, perforin concentrations in the respec-
tive supernatants in +Arg medium (60 pg/ml 616 pg/ml)
compared with –Arg medium (48 pg/ml 611 pg/ml) were not
significantly different (p = 0.153).
Discussion
The adaptive immune response is controlled by the regulated
availability of specific amino acids [30]. Our study highlights the
following two novel aspects: (i) human T cell functions were
analyzed in an antigen specific context (and not upon polyclonal
stimulation) and suppression of IFN-c secretion, granzyme B
mobilization and proliferation were recapitulated; (ii) we show that
important human T cell functions – chemotaxis, calcium signaling,
cytotoxicity – are completely preserved in the absence of arginine.
Peptide specific T cell activation in the context of MDSC-
induced arginine depletion was already analyzed in several murine
models. Murine MDSC from tumor bearing mice can inhibit the
OVA peptide antigen specific production of IFN-c by CD8+ T
cells via oxidative stress [31,32] or influenza hemagglutinin [31] or
OVA peptide specific [33] T cell proliferation via arginase-
mediated arginine depletion. Inhibition of prostate carcinoma
specific, tumor infiltrating effector lymphocytes could be reversed
and CD8+ cytotoxicity and tumor cell apoptosis increased upon
arginase and NOS inhibition in a murine tumor model [14]. Also,
several murine models exist that demonstrate MDSC- or arginase-
mediated inhibition of T cell priming. Expansion of naı¨ve
transgenic OVA specific CD4+ T cells [34] and hemagglutinin
specific CD8+ T cells [34] is inhibited by murine tumor-induced
MDSC [34] or regulatory DC via arginase [35]. Also, in the
murine NeuT tumor model, naı¨ve CD8+ T cell priming and
antitumoral cytotoxicity is inhibited by arginase-expressing tumor
infiltrating DC [36].
In humans, various studies have demonstrated the inhibition of
polyclonal or alloreactive T cell stimulation via depletion of
arginine. Human immature myeloid cells from advanced stage
cancer patients inhibit allogeneic or tetanus toxoid specific T cell
responses [37], while CD14+ myeloid suppressor cells in melano-
ma patients inhibit polyclonally activated IFN-c secretion and
proliferation of human T cells [38]. Inhibition of the human
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Figure 5. Arginine-independent cytotoxicity of tumor antigen specific T cells. A Expanded MART-1aa26–35*A27L specific CD8
+ T cells of 3 HD
were preincubated for 24 h in the presence (+Arg, 1000 mM) or absence (2Arg) of arginine and subsequently stimulated with MART-1aa26–35*A27L
peptide or control (irrelevant) peptide pulsed T2 cells for 4 h in a [51Cr]-Chromium release assay. Specific lysis of peptide loaded T2 cells upon
incubation with MART-1aa26–35*A27L specific CD8
+ T cells in various E:T ratios (1:1–20:1) with/without arginine was determined in duplicates. Shown is
the antigen specific lysis in % which is the specific lysis investigated with MART-1aa26–35*A27L loaded T2 cells minus specific lysis with control peptide
loaded T2 cells. B Quantitative determination of antigen specific T cells was performed by MART-1aa26–35*A27L tetramer analysis and is displayed as %
of CD8+CD3+ T cells (analyzed before separation into the +Arg/2Arg groups) together with the results for the [51Cr]-Chromium release assay for each
individual experiment.
doi:10.1371/journal.pone.0063521.g005
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MDSC effector mechanisms iNOS and arginase restores T cell
proliferation after polyclonal activation via anti-CD3/CD28-
coated beads [12] or PMA/PHA [14]. Our current study extends
these analyses by demonstrating the impact of arginine depletion
on peptide specific human T cell activation in two different
antigen systems.
Our findings of unimpaired T cell chemotaxis, calcium
signaling, perforin secretion and cytotoxicity extend our recent
observation that certain cytokines (IL-2, IL-6 and IL-8) can be
synthesized by activated human T cells in an arginine-independent
way in contrast to severely suppressed cytokines like IFN-c, IL-10
or TNF-b [10]. In earlier analysis we could already show that e.g.
CD69 upregulation on T cells is even enhanced upon activation in
the absence of arginine [9]. The unimpaired calcium flux
complements our recent observation that another T cell signaling
pathway, namely PI3K activity measured as Akt phosphorylation,
is also uncompromised and even hyperactive in the absence of
arginine upon T cell stimulation via TCR while e.g. ERK activity
is suppressed [10].
It remains to be analyzed how human T cells can preserve their
cytotoxic effector function even though arginine deficiency leads to
a reduction in granzyme B mobilization (Fig. 4B, 6C). We can
exclude a participation of the CD95/CD95L system since our
K562-A2 target cells do not express CD95 (data not shown). Also,
a participation of TRAIL is rather unlikely, since we did not
observe TRAIL expression on the T cells within the 4 h time
period of the cytotoxicity assay (data not shown). We saw arginine-
independent perforin secretion in the three different antigen-
specific T cell activation systems and this might be involved in the
unimpaired T cell cytotoxicity in the context of arginine
deficiency. Since also other proteins like e.g. granulysin might
contribute to this phenomenon, further studies are needed to
clarify our novel findings.
We demonstrated recently that cofilin dephosphorylation and
actin reorganization are impaired upon activation of human
primary T cells in the absence of arginine [10]. Since SDF-1a
induced T cell chemotaxis also requires actin reorganization [39]
and hyperphosphorylation of cofilin can interfere with SDF-1a
induced human T cell migration [40] we would have anticipated
an impaired chemotactic T cell movement in arginine-free
medium. This is clearly not the case (Fig. 1A) and might be
explained by our previous observation that migration of human T
cells depends on cofilin-mediated actin reorganization only in the
3D setting (e.g. in vitro matrigel migration) but not (as in our
experiments) in 2D circumstances [41]. Further studies are needed
to address the redundant signaling pathways in human T cells that
allow sufficient actin reorganization for uncompromised chemo-
taxis in the absence of arginine.
Human MDSC induced T cell immunosuppression clearly
differs with respect to the prevailing MDSC-associated immuno-
Figure 6. Impact of arginine depletion on cytotoxic capacity,
cytokine secretion and proliferation of human CD8+ CMV
antigen specific T cells expanded from the natural repertoire.
Expanded CMV pp65aa495–503 specific T cells of 2 HD (N,m) and a CMV
pp65aa495–503 specific T cell clone (&) were activated with pp65aa495–503
peptide pulsed K562-A2 cells. A Antigen specific tumor cell cytotoxicity
was analyzed by [51Cr]-Chromium release assay at various E:T ratios and
peptide concentrations (100 nM, 10 nM, 1 nM) in the presence (–––) or
absence (- - -) of arginine. In parallel, expanded CMV pp65aa495–503
specific T cells were incubated with pp65aa495–503 peptide pulsed K562-
A2 target cells for 48 h (B–D) or 120 h (E) at an E:T ratio of 20:1.
Supernatant was harvested and concentrations of IFN-c (B), granzyme B
(C) and perforin (D) were determined by ELISA. Data in A–D are
representative of 3 different experiments with a total of 5 independent
HD. E Reduced proliferation of CMV pp65aa495–503 specific T cells in the
absence (2Arg) compared to presence (+Arg, 1000 mM) of arginine, as
determined by CFSE staining, gated on all CD3+ T cells within the assay
mixture. One representative experiment (total: 3) is shown in (E).
doi:10.1371/journal.pone.0063521.g006
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suppressive mechanism. While our data show that arginine
depletion has no negative impact on CD8+ T cell mediated
cytotoxicity, others reported that peptide specific IFN-c secretion
and cytolytic activity as well as the tetanus-toxoid specific
proliferation of MART-1 tumor antigen specific T cells can be
inhibited by oxidative stress induced by MDSC of renal cell
carcinoma patients [32]. In contrast to our study, in which we
analyzed activation of freshly generated MART-1 tumor antigen
specific T cells, the authors used a long-term MART-1 specific T
cell clone, which does not necessarily reflect the situation in vivo of
de novo vaccinated patients. Furthermore, tumor-derived lactic
acid, like arginine depletion a powerful immunosuppressive
effector mechanism, also shows some degree of split T cell
inhibition: while T cell proliferation and cytokine secretion are
severely suppressed, T cell cytotoxicity is decreased to 50% [42].
All these studies clearly complement each other in their analysis of
different tumor immune escape mechanisms and their impact on
tumor antigen specific CD8+ T cells.
While we demonstrate unimpaired human CD8+ T cell
cytotoxicity even in the complete absence of arginine, long term
immunological tumor control supposedly depends on effective
production of various effector cytokines and proapoptotic factors
(e.g. granzyme B, perforin) as well as antitumoral T cell expansion
and differentiation. We therefore hypothesize that different tumor-
induced immunosuppressive effector pathways synergize and
eventually lead to fundamental T cell paralysis within the tumor
microenvironment.
In summary, we have demonstrated an unexpected selective
regulation of human T cell effector functions in the absence of
arginine: While antigen specific proliferation and secretion of IFN-
c and granzyme B are strongly suppressed, T cells completely
preserve their cytotoxic and chemotactic functions. Our data
highlight the complexity of tumor-induced immune escape
mechanisms and emphasize the need for counterregulatory
immunotherapeutic strategies to enhance the endogenous or
therapeutically-induced anti-tumor immune response.
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